NCT05083780View on ClinicalTrials.gov

Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 28, 2025

Study Completion Date

December 30, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

Chlorphenesin Carbamate, Hydroxychloroquine

In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

Oncocross Co. Ltd.

INDUSTRY

collaborator

CytoGen, Inc.

INDUSTRY

lead

Changhoon Yoo

OTHER